Bioengineered Anti-PD-L1 Functionalized Nanoplatform for Targeted Delivery and Tumor Immune Reprogramming Against Colorectal Cancer.

ABSTRACT: Colorectal cancer (CRC) remains a major clinical challenge owing to its immunosuppressive tumor microenvironment and limited targeting therapeutic efficiency. Developing innovative strategies that integrate immune activation with enhanced tumor-targeting ability is urgently needed. Herein, we reported a bioengineered exosome drug delivery nanoplatform (Apatinib-Exo^aPD-L1), in which HEK293T-derived exosomes were surface functionalized with anti-PD-L1 antibody (aPD-L1) and encapsulated the tyrosine kinase inhibitor Apatinib, aiming to enhance the tumor-targeted immunotherapy against CRC. Apatinib-Exo^aPD-L1 exhibited efficient tumor-targeting capability and prolonged systemic circulation, attributed to aPD-L1 modification, resulting in markedly enhanced antitumor efficac

SUBMITTER: Liu M 

PROVIDER: S-EPMC12699071 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature